The Consortium’s work represents the largest and most comprehensive assessment of the effects of SGLT2 inhibitors and has been featured in leading general medical and specialty journals.
SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: A meta-analysis
Efficacy and safety of SGLT2 inhibitors with and without GLP-1 receptor agonists: A SMART-C collaborative meta-analysis of randomised controlled trials